Living With & Finding StrengthEvery chronic and life-threatening condition comes with its own symptoms and challenges, and while each individual's experience is unique, there is wisdom to be found in learning how others have... By Emily Downward1 min readBookmark for laterReactions 0 reactions Comments2 comments
Living With Blood Cancer: a Podcast Interview with Cindy ChmielewskiCindy Chmielewski has been living with multiple myeloma, a form of blood cancer, since 2008. She goes by the handle “Myeloma Teacher” online, sharing information about the disease, research updates... By Emily Downward1 min readBookmark for laterReactions 0 reactions Comments2 comments
Living With: Podcast Interview with Daniel MalitoDaniel Malito is an advocate on two of Health Union’s communities: RheumatoidArthritis.net and Blood-Cancer.com. I had the opportunity to interview him for the Health Union podcast, Living With. We spoke... By Emily Downward1 min readBookmark for laterReactions 0 reactions Comments5 comments
Research Shows Cancer Likely to Become More Deadly than Heart DiseaseHeart disease is the leading cause of death in Americans, but new research shows that cancer is likely to surpass heart disease as the number one killer in 2020, especially... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves First Biosimilar to Rituxan & New Drug for AMLOn November 28, 2018, the U.S. Food and Drug Administration (FDA) approved two new products that affect the blood cancer community: Truxima (rituximab-abbs) and Xospata (gilteritinib). Truxima is approved to... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves 2 New Treatments for AML in Older Adults & Patients with ComorbiditiesThe U.S. Food and Drug Administration (FDA) recently approved two new treatment options for certain people with acute myeloid leukemia (AML): Daurismo™ (glasdegib) and Venclexta® (venetoclax) in combination with other... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
Precision Medicine Research in Blood CancerI recently attended a fascinating discussion in precision medicine in cancer care. Precision medicine is the tailoring of treatment for the specific needs and unique characteristics of a patient and... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves New Immunotherapy Combination for Multiple MyelomaThe U.S. Food and Drug Administration (FDA) recently approved Empliciti (elotuzumab) as part of a combination treatment to treat certain people with relapsed or refractory multiple myeloma (MM). Empliciti can... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves First Next-Generation Sequencing Test for Minimal Residual Disease of ALL and Multiple MyelomaOn September 28, 2018, the U.S. Food and Drug Administration (FDA) approved the first next-generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Approves Copiktra for CLL/SLL and Follicular LymphomaOn September 24, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment for certain types of blood cancer: Copiktra (duvelisib). Manufactured by Verastem, Copiktra is approved to... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
What is Mantle Cell Lymphoma?Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma (NHL) that arises from B cell lymphocytes, a type of white blood cell that helps fight infection by creating antibodies... By Emily Downward3 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Lumoxiti for Hairy Cell LeukemiaOn September 13, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment option for adults with hairy cell leukemia (HCL) who have tried at least two prior... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
Life with Lymphoma: Highlights from our 2018 Blood Cancer In America SurveyOf those who responded to our 2018 Blood Cancer In America survey, 32% were impacted by lymphoma, a type of blood cancer found in the lymphatic system. The two major... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
The Fears & Worries of Life with Blood CancerIn our 2018 Blood Cancer In America survey, people living with blood cancer shared their perspective on how the condition has impacted their life. Survey results indicated that blood cancer... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments3 comments
Differences in Blood Cancer ExperienceIn our 2018 Blood Cancer In America survey, over 2,500 people impacted by blood cancer shared their experiences about diagnosis, treatment, and living with blood cancer. Blood cancer is an... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Expands Venclexta Approval for Broader Treatment of CLL and SLLThe U.S. Food and Drug Administration (FDA) has recently expanded the approval for Venclexta (venetoclax). Venclexta is now approved to treat chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
Psychosocial Considerations for Children with CancerA diagnosis of cancer carries a psychosocial and physical impact for anyone, and for the youngest patients, there are added considerations. Because they are in the midst of development, children... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
Expanded Approval for Darzalex – Newly Diagnosed, Transplant-Ineligible Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has recently expanded the usage of Darzalex (daratumumab): it is now approved to be used in combination with Velcade (bortezomib), melphalan, and prednisone... By Emily Downward2 min readBookmark for laterReactions 0 reactions Comments0 comments
CAR T-Cell Therapy Kymriah Now Approved for Adult Diffuse Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) recently expanded the approval of Kymriah™ (tisagenlecleucel) to include adults with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma... By Emily Downward3 min readBookmark for laterReactions 0 reactions Comments0 comments